P H Dennehy

Summary

Affiliation: Rhode Island Hospital
Country: USA

Publications

  1. ncbi Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States
    Penelope H Dennehy
    Department of Pediatrics, Rhode Island Hospital, Providence, Rhode Island 02903, USA
    Pediatrics 122:e1062-6. 2008
  2. ncbi Rotavirus infection: an update on management and prevention
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Hasbro Children s Hospital, Providence, RI, USA
    Adv Pediatr 59:47-74. 2012
  3. ncbi Effects of vaccine on rotavirus disease in the pediatric population
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Department of Pediatrics, Hasbro Children s Hospital, The Alpert Medical School of Brown University, Providence, Rhode Island, USA
    Curr Opin Pediatr 24:76-84. 2012
  4. ncbi Rotavirus vaccines--an update
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital and the Department of Pediatrics, Brown Medical School, 593 Eddy Street, Providence, RI 02903, United States
    Vaccine 25:3137-41. 2007
  5. ncbi Rotavirus vaccines - success after failure
    Penelope H Dennehy
    The Warren Alpert Medical School of Brown University, USA
    Med Health R I 90:321-4. 2007
  6. ncbi A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United Sta
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA
    Vaccine 24:3780-1. 2006
  7. ncbi Acute diarrheal disease in children: epidemiology, prevention, and treatment
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital, Providence, 02903, USA
    Infect Dis Clin North Am 19:585-602. 2005
  8. ncbi Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital and the Department of Pediatrics, Brown Medical School, Providence, 02903, USA
    Pediatr Infect Dis J 24:481-8. 2005
  9. ncbi Rotavirus vaccines: an update
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital and Brown Medical School, Providence, Rhode Island 02903, USA
    Curr Opin Pediatr 17:88-92. 2005
  10. ncbi The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine
    Penelope H Dennehy
    Hasbro Children s Hospital, Providence, RI 02903, USA
    Int J Infect Dis 11:S36-42. 2007

Collaborators

Detail Information

Publications26

  1. ncbi Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States
    Penelope H Dennehy
    Department of Pediatrics, Rhode Island Hospital, Providence, Rhode Island 02903, USA
    Pediatrics 122:e1062-6. 2008
    ..This study was conducted to confirm the absence of immune interference of 2 doses of RIX4414 (Rotarix) on routine infant vaccinations in the United States...
  2. ncbi Rotavirus infection: an update on management and prevention
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Hasbro Children s Hospital, Providence, RI, USA
    Adv Pediatr 59:47-74. 2012
    ....
  3. ncbi Effects of vaccine on rotavirus disease in the pediatric population
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Department of Pediatrics, Hasbro Children s Hospital, The Alpert Medical School of Brown University, Providence, Rhode Island, USA
    Curr Opin Pediatr 24:76-84. 2012
    ..As rotavirus vaccines are implemented, studies have been undertaken that assess the effects of vaccination on rotavirus disease in children. This review summarizes the results of these studies...
  4. ncbi Rotavirus vaccines--an update
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital and the Department of Pediatrics, Brown Medical School, 593 Eddy Street, Providence, RI 02903, United States
    Vaccine 25:3137-41. 2007
    ..These new safe and effective rotavirus vaccines offer the best hope of reducing the toll of acute rotavirus gastroenteritis in both developed and developing countries...
  5. ncbi Rotavirus vaccines - success after failure
    Penelope H Dennehy
    The Warren Alpert Medical School of Brown University, USA
    Med Health R I 90:321-4. 2007
  6. ncbi A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United Sta
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA
    Vaccine 24:3780-1. 2006
    ..5% in low dose group) was seen between vaccine groups. Two doses of either dosage level of HRV vaccine administered concurrently with routine childhood vaccines to healthy infants were well tolerated and elicited excellent vaccine takes...
  7. ncbi Acute diarrheal disease in children: epidemiology, prevention, and treatment
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital, Providence, 02903, USA
    Infect Dis Clin North Am 19:585-602. 2005
    ....
  8. ncbi Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital and the Department of Pediatrics, Brown Medical School, Providence, 02903, USA
    Pediatr Infect Dis J 24:481-8. 2005
    ..Rotavirus is a major cause of gastroenteritis in children worldwide and is estimated to be responsible for more than 500,000 physician visits, 50,000 hospitalizations and 20 deaths in the United States each year...
  9. ncbi Rotavirus vaccines: an update
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital and Brown Medical School, Providence, Rhode Island 02903, USA
    Curr Opin Pediatr 17:88-92. 2005
    ..Vaccination is the only control measure likely to have a significant impact on the incidence of severe dehydrating rotavirus disease...
  10. ncbi The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine
    Penelope H Dennehy
    Hasbro Children s Hospital, Providence, RI 02903, USA
    Int J Infect Dis 11:S36-42. 2007
    ..Rotavirus gastroenteritis is a significant cause of morbidity and mortality...
  11. ncbi Active immunization in the United States: developments over the past decade
    P H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital, Providence, Rhode Island 02903, USA
    Clin Microbiol Rev 14:872-908, table of contents. 2001
    ....
  12. ncbi A prospective case-control study of the role of astrovirus in acute diarrhea among hospitalized young children
    P H Dennehy
    Department of Pediatrics, Rhode Island Hospital and Brown Medical School, Providence, Rhode Island 02903, USA
    J Infect Dis 184:10-5. 2001
    ..Astrovirus, for which only rehydration therapy is required, should be considered as another common diarrheal pathogen in children <2 years old...
  13. ncbi Rotavirus vaccine and intussusception. Where do we go from here?
    P H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital, Providence, Rhode Island
    Infect Dis Clin North Am 15:189-207, x-xi. 2001
    ..The future of rotavirus vaccine is dependent on the reasons for this association that have yet to be discovered...
  14. ncbi Rotavirus vaccines: an overview
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA
    Clin Microbiol Rev 21:198-208. 2008
    ..These new safe and effective rotavirus vaccines offer the best hope of reducing the toll of acute rotavirus gastroenteritis in both developed and developing countries...
  15. ncbi A case-control study to determine risk factors for hospitalization for rotavirus gastroenteritis in U.S. children
    Penelope H Dennehy
    Hasbro Children s Hospital and Brown Medical School, Department of Pediatrics, Division of Infectious Diseases, Providence, RI 02903
    Pediatr Infect Dis J 25:1123-31. 2006
    ....
  16. ncbi Comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetravalent rhesus rotavirus vaccine. US Rhesus Rotavirus Vaccine Study Group
    P H Dennehy
    Department of Pediatrics, Rhode Island Hospital, Providence 02903, USA
    Pediatr Infect Dis J 15:1012-8. 1996
    ..To compare the safety and immunogenicity of two dosages of tetravalent rhesus rotavirus vaccine (RRV-TV) and the effect of age at dosing...
  17. ncbi Evaluation of the ImmunoCardSTAT! rotavirus assay for detection of group A rotavirus in fecal specimens
    P H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital, and Department of Pediatrics, Brown University School of Medicine, Providence, Rhode Island 02903, USA
    J Clin Microbiol 37:1977-9. 1999
    ..0, 100, 100, and 93.4% for ICS-RV; 95.5, 100, 100, and 95.0% for Rotaclone; and 97.0, 96.5, 97.0, and 96.5% for TestPack. ICS-RV was sensitive and specific and was relatively simple to perform and interpret...
  18. ncbi Rhesus rotavirus vaccine effectiveness and factors associated with receipt of vaccine
    Mary Allen Staat
    Cincinnati Children s Hospital Medical Center, Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
    Pediatr Infect Dis J 25:1013-8. 2006
    ..The objective of this study was to determine the effectiveness of the RotaShield vaccine against rotavirus gastroenteritis requiring hospitalization and to evaluate factors associated with vaccine receipt...
  19. ncbi Transmission of rotavirus and other enteric pathogens in the home
    P H Dennehy
    Brown University School of Medicine and Division of Pediatric Infectious Diseases, Rhode Island Hospital, Providence 02903, USA
    Pediatr Infect Dis J 19:S103-5. 2000
    ....
  20. ncbi Serologic responses by immunoblot following natural infection with rotavirus serotypes G1 and G4 in children
    R E Begue
    Department of Pediatrics, Brown University School of Medicine, Providence, Rhode Island, USA
    J Med Virol 56:52-7. 1998
    ..The data show the antigenic predominance of internal proteins VP6 and VP2. Homotypic antibodies developed against VP7 but not against VP4 in most cases, while heterotypic antibodies were infrequent...
  21. ncbi Rotavirus vaccines: an update
    Penelope H Dennehy
    Division of Pediatric Infectious Diseases, Rhode Island Hospital and Brown Medical School, Providence, RI, USA
    Pediatr Infect Dis J 25:839-40. 2006
  22. ncbi Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants
    H Fred Clark
    University of Pennsylvania School of Medicine, Philadelphia, and Merck and Co, Inc, West Point, Pennsylvania 19486, USA
    J Pediatr 144:184-90. 2004
    ..CONCLUSIONS: QRV was generally well tolerated, immungenic, and highly effective against rotavirus gastroenteritis...
  23. ncbi Prevalence of group C rotavirus among children in Rhode Island, United States
    Mathew D Esona
    Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
    J Clin Virol 42:221-4. 2008
    ..Group C rotavirus causes sporadic cases and outbreaks of acute diarrhea in humans but its burden as a cause of severe gastroenteritis in children remains unclear...
  24. ncbi Safety and immunogenicity of palivizumab (Synagis) administered for two seasons
    Donald Null
    Primary Children's Medical Center, Salt Lake City, UT, USA
    Pediatr Infect Dis J 24:1021-3. 2005
    ..The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated...
  25. ncbi Prevention of influenza: recommendations for influenza immunization of children, 2007-2008
    Joseph A Bocchini
    Pediatrics 121:e1016-31. 2008
    ..However, oseltamivir and zanamivir can be prescribed for treatment or chemoprophylaxis, because influenza A and B strains remain susceptible...
  26. ncbi Rotavirus infection alters peripheral T-cell homeostasis in children with acute diarrhea
    Yuhuan Wang
    Division of Viral Diseases, Scientific Resources Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Virol 81:3904-12. 2007
    ....